- Amneal to Participate at Upcoming Investor Conference
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
- Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Tuesday, Amneal Pharmaceuticals Inc (AMRX:NSQ) closed at 6.79, -2.72% below its 52-week high of 6.98, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.53 |
---|---|
High | 6.90 |
Low | 6.44 |
Bid | 6.61 |
Offer | 6.92 |
Previous close | 6.79 |
Average volume | 1.32m |
---|---|
Shares outstanding | 308.65m |
Free float | 120.40m |
P/E (TTM) | -- |
Market cap | 2.10bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼